ACXP · Acurx Pharmaceuticals, Inc. · Exempt Offerings
$0.99
-0.05 (-4.37%)
At close · Nov 12
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 13, 2026
Market Cap
$5.97M
Shares
6.06M
Volume · Nov 12
159.19K
Avg daily vol (3M)
124.59K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2026-04-29 | New | Pharmaceuticals | $4,587,473 | $4,587,473 | 06b |
| 2025-06-27 | New | Pharmaceuticals | $3,978,664 | $3,978,664 | 06b |
| 2025-05-20 | New | Pharmaceuticals | $12,000,000 | $0 | 06b |
| 2025-03-21 | New | Pharmaceuticals | $3,376,350 | $3,376,350 | 06b |
| 2025-01-17 | New | Pharmaceuticals | $2,404,259 | $2,404,259 | 06b |
| 2020-01-17 | New | Biotechnology | $6,000,000 | $455,000 | 06b |
Showing 1–6 of 6 filings
Key facts
CIK
1736243
CUSIP
00510M203
13F (30d)
10 filings
10 filers
Visit website
Investor relations